LeMaitre Vascular (NASDAQ:LMAT) Releases Q1 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.480-0.530 for the period, compared to the consensus estimate of 0.510. The company issued revenue guidance of $56.7 million-$58.7 million, compared to the consensus revenue estimate of $58.1 million. LeMaitre Vascular also updated its FY 2025 guidance to 2.150-2.320 EPS.

LeMaitre Vascular Trading Down 8.1 %

Shares of LMAT stock traded down $8.06 during trading hours on Friday, hitting $91.85. The company’s stock had a trading volume of 442,236 shares, compared to its average volume of 137,287. The company has a 50 day moving average of $96.89 and a 200 day moving average of $94.73. LeMaitre Vascular has a 12-month low of $62.39 and a 12-month high of $109.58. The stock has a market cap of $2.07 billion, a PE ratio of 50.19, a price-to-earnings-growth ratio of 2.22 and a beta of 0.96.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.49. The business had revenue of $55.81 million during the quarter, compared to analysts’ expectations of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. As a group, analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

LMAT has been the topic of a number of analyst reports. StockNews.com cut LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, December 13th. Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective on the stock. Barrington Research downgraded LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday. Finally, Oppenheimer lowered shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research note on Friday. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.25.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.